今海医疗科技(02225) - 2025 - 年度业绩

Supplementary Announcement Overview This announcement provides supplementary information to the company's 2024 annual report, focusing on risk management remedies and share option scheme updates Purpose and Background of the Announcement This announcement supplements the company's 2024 annual report, detailing risk management remedies and share option scheme updates - This document is a supplementary announcement by Jinhai Medical Technology Co., Ltd. (Stock Code: 2225) regarding its 2024 annual report[2] - The announcement aims to provide supplementary information beyond the annual report, covering risk management, internal control, and the share option scheme[3][4] Risk Management and Internal Control Enhancement Measures The board has implemented various remedial measures to strengthen risk management and internal controls, ensuring compliance with listing rules Details of Remedial Measures The Board implemented risk management and internal control remedies to prevent future non-compliance and ensure adherence to Listing Rules Chapter 14 - The Board confirms its responsibility to maintain sound and effective risk management and internal control systems, having acted on identified deficiencies[4] - The company has implemented several remedial measures to ensure future compliance with Listing Rules Chapter 14, including strengthening internal control policies for notifiable transactions, providing internal training on Listing Rules for directors and management, hiring qualified staff to oversee future transactions and size test calculations, and seeking external professional advice for all proposed transactions[7][5] Share Option Scheme Update This section provides an update on the share option scheme, specifically detailing the number of options available for grant Number of Share Options Available for Grant The announcement details the number of share options available for grant under the scheme mandate and service provider sub-limits for fiscal year 2024, showing zero options at year-end Share Options Available for Grant | Category | January 1, 2024 | December 31, 2024 | | :--- | :--- | :--- | | Scheme Mandate Limit | 517,000,000 | 0 | | Service Provider Sub-limit | 51,700,000 | 0 | Note: Numbers have been adjusted with reference to the share split effective December 10, 2024 Other Information This section confirms the consistency of the annual report's other contents and lists the current composition of the Board of Directors Concluding Remarks and Board Composition The announcement confirms the annual report's other contents remain unchanged, except for supplementary details, and lists the Board's composition as of the announcement date - All other information within the annual report remains unchanged, except for the supplementary details disclosed in this announcement[8] - As of the announcement date, the Board of Directors comprises eight members: three executive directors, two non-executive directors, and three independent non-executive directors[9]